The lawyer who successfully argued the KSR v. Teleflex case before the U.S. Supreme Court in 2007 is asking the high court to revisit the question of who decides a patent's obviousness. James Dabney says the Federal Circuit has established precedent that's out of line with the Court's KSR ruling.

Michael Jakes was ready to argue for a more expansive business method patent standard than the Federal Circuit's "machine or transformation" test, but the justices haven't seemed ready to accept his position.

A failed bid by Highmark Inc. for an en banc Federal Circuit rehearing exposed a clear divide on the court over the deference that should be afforded to trial court judges weighing attorney fee requests.

King & Spalding's Daryl Joseffer helped a University of Illinois professor resuscitate headline-grabbing claims that Nikon stole his billion-dollar idea for improving liquid crustal display manufacturing.

The U.S. Supreme Court declined Tuesday to hear arguments that the International Trade Commission should close its doors to certain kinds of nonpracticing entities.

In the bitter fight over wind turbine technology, did Mitsubishi and its lawyers make a mistake by claiming fraud against GE in an Arkansas antitrust case instead of making the allegations as an inequitable conduct defense in GE's Dallas infringement suit?

These are two companies that seriously don't get along: A month after losing the biggest patent infringement verdict in U.S. history to J&J's Centocor unit, Abbott has filed a new case claiming that a Centocor psoriasis drug infringes one of its patents.

Cameron and Tyler Winklevoss aren't taking their Facebook case to the Supreme Court. But that doesn't mean the twins have given up.

We've been hearing that patent litigation is a luxury some companies are concluding they just can't afford in this economy. Unless the profitability of a $4.5 billion drug is at stake. On Friday, Abbott Biotechnology Limited filed a patent infringement case in the District of Massachusetts against Centocor Ortho Biotech, a unit of Johnson & Johnson, in an effort to protect its rheumatoid arthritis drug, Humira.